China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Pharmaceutical Group Ltd. reported a robust results estimate for its subsidiary Dong-E-E-Jiao, with projected net profit for the first half of 2024 increasing by 31% to 43%. This surge is attributed to Dong-E-E-Jiao’s effective growth strategies and expansion in health consumer products, along with their commitment to advancing traditional Chinese medicine. The company anticipates continued development and innovation in the nourishment and health preservation sectors.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
